Studies of the potential genotoxic effects of furoxans: The case of CAS 1609 and of the water-soluble analogue of CHF 2363

Toxicology Letters

Volumn 178, Issue 1, 2008, Pages 44-51

  Balbo, S ^a   Lazzarato, L ^a   Di Stilo, A ^a   Fruttero, R ^a   Lombaert, N ^b   Kirsch Volders, M ^b  

^a UNIVERSITY OF TURIN   (Italy)

^b VRIJE UNIVERSITEIT BRUSSEL   (Belgium)

Author keywords

Furoxans; NO induced apoptosis; NO induced genotoxicity; NO induced mutagenicity

Indexed keywords

4 ETHOXY 3 PHENYLSULFONYLFUROXAN; 4 HYDROXYMETHYLFUROXAN 3 CARBOXAMIDE; CAS 1609; CHF 2363; FURAZAN DERIVATIVE; NITRIC OXIDE; OXYHEMOGLOBIN; UNCLASSIFIED DRUG; WATER;

ANIMAL CELL; ARTICLE; CELL VIABILITY; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; CYTOTOXICITY; DRUG EFFECT; GENOTOXICITY; HUMAN; HUMAN CELL; NONHUMAN; PRIORITY JOURNAL; RAT;

APOPTOSIS; CELL SURVIVAL; COMET ASSAY; DNA DAMAGE; HUMANS; LEUKOCYTES, MONONUCLEAR; MICRONUCLEUS TESTS; MUTAGENS; NITRIC OXIDE; OXADIAZOLES; OXYHEMOGLOBINS; SOLUBILITY; WATER;

EID: 41749086410     PISSN: 03784274     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.toxlet.2008.02.001     Document Type: Article

References (32)

1. Ahlner J., Andersson R.G., Torfgard K., and Axelsson K.L. Organic nitrate esters: clinical use and mechanisms of actions. Pharmacol. Rev. 43 3 (1991) 351-423
2. Andreassi M.G., Picano E., Del Ry S., Botto N., Colombo M.G., Giannessi D., Lubrano W., Vassalle C., and Biagini A. Chronic long term nitrate therapy: possible cytogenetic effect in humans?. Mutagenesis 16 6 (2001) 517-521
3. Bohn H., Brendel J., Martorana P.A., and Schonafinger K. Cardiovascular actions of the furoxan CAS 1609 a novel nitric oxide donor. Br. J. Pharmacol. 114 8 (1995) 1605-1612
4. Boschi D., Tron G.C., Lazzarato L., Chegaev K., Cena C., Di Stilo A., Giorgis M., Bertinaria M., Fruttero R., and Gasco A. NO-donor phenols: a new class of products endowed with antioxidant and vasodilator properties. J. Med. Chem. 49 10 (2006) 2886-2897
5. Burney S., Caulfield J.L., Niles J.C., Wishnok J.S., and Tannenbaum S.R. The chemistry of DNA damage from nitric oxide and peroxynitrite. Mutat. Res. 424 1/2 (1999) 37-49
6. Chegaev K., Lazzarato L., Tosco P., Cena C., Marini E., Rolando B., Carrupt P.A., Fruttero R., and Gasco A. NO-donor COX-2 inhibitors. New nitrooxy-substituted 1,5-diarylimidazoles endowed with COX-2 inhibitory and vasodilator properties. J. Med. Chem. 50 7 (2007) 1449-1457
7. Chen Z., and Stamler J.S. Bioactivation of nitroglycerin by the mitochondrial aldehyde dehydrogenase. Trends Cardiovasc. Med. 16 8 (2006) 259-265
8. Christen S., Gee P., and Ames B.N. Mutagenicity of nitric oxide in base pair-specific Salmonella tester strains: TA7000 series. Methods Enzymol. 269 (1996) 267-278
9. Civelli M., Giossi M., Caruso P., Razzetti R., Bergamaschi M., Bongrani S., and Gasco A. The involvement of the release of nitric oxide in the pharmacological activity of the new furoxan derivative CHF 2363. Br. J. Pharmacol. 118 4 (1996) 923-928
10. De Boeck M., Lison D., and Kirsch-Volders M. Evaluation of the in vitro direct and indirect genotoxic effects of cobalt compounds using the alkaline comet assay Influence of interdonor and interexperimental variability. Carcinogenesis 19 11 (1998) 2021-2129
11. De Boeck M., Lombaert N., De Backer S., Finsy R., Lison D., and Kirsch-Volders M. In vitro genotoxic effects of different combinations of cobalt and metallic carbide particles. Mutagenesis 18 2 (2003) 177-186
12. De Boeck M., Kirsch-Volders M., and Lison D. Cobalt and antimony: genotoxicity and carcinogenicity. Mutat. Res. 533 1/2 (2003) 135-152 (erratum in: Mutat. Res. 548 (1-2), 127-128, 2004)
13. Feelisch M., Schonafinger K., and Noack E. Thiol-mediated generation of nitric oxide accounts for the vasodilator action of furoxans. Biochem. Pharmacol. 44 6 (1992) 1149-1157
14. Fenech M. The in vitro micronucleus technique. Mutat. Res. 455 1/2 (2000) 81-95
15. Gal A., and Wogan G.N. Mutagenesis associated with nitric oxide production in transgenic SJL mice. Proc. Natl. Acad. Sci. U.S.A. 93 26 (1996) 15102-15107
16. Gasco A., and Schonafinger K. The NO-releasing heterocycles. In: Wang P.G., Cai T.B., and Taniguchi N. (Eds). Nitric Oxide Donors (2005), Wiley-VCH, Weinheim 131-175
17. Hussain R.F., Nouri A.M., and Oliver R.T. A new approach for measurement of cytotoxicity using colorimetric assay. J. Immunol. Methods 160 1 (1993) 89-96
18. Ibe W., Bartels W., Lindemann S., Grosser T., Buerke M., Boissel J.P., Meyer J., and Darius H. Involvement of PKC and NF-kappaB in nitric oxide induced apoptosis in human coronary artery smooth muscle cells. Cell Physiol. Biochem. 11 5 (2001) 231-240
19. Kerwin Jr. J.F., Lancaster Jr. J.R., and Feldman P.L. Nitric oxide: a new paradigm for second messengers. J. Med. Chem. 38 22 (1995) 4343-4362
20. Kirsch-Volders M., Sofuni T., Aardema M., Albertini S., Eastmond D., Fenech M., Ishidate Jr. M., Kirchner S., Lorge E., Morita T., Norppa H., Surralles J., Vanhauwaert A., and Wakata A. Report from the in vitro micronucleus assay working group. Mutat. Res. 540 2 (2004) 153-163 (erratum in: Mutat. Res. 564, 1, 97-100)
21. Lee D.H., and Pfeifer G.P. Mutagenesis induced by the nitric oxide donor sodium nitroprusside in mouse cells. Mutagenesis 22 1 (2007) 63-67
22. Lin W., Xue H., Liu S., He Y., Fu J., and Zhou Z. Genotoxicity of nitric oxide produced from sodium nitroprusside. Mutat. Res. 413 (1998) 121-127
23. Liu R.H., and Hotchkiss J.H. Potential genotoxicity of chronically elevated nitric oxide: a review. Mutat. Res. 339 2 (1995) 73-89
24. Nguyen T., Brunson D., Crespi C.L., Penman B.W., Wishnok J.S., and Tannenbaum S.R. DNA damage and mutation in human cells exposed to nitric oxide in vitro. Proc. Natl. Acad. Sci. U.S.A. 89 7 (1992) 3030-3034
25. Ohshima H., and Bartsch H. Chronic infections and inflammatory processes as cancer risk factors: possible role of nitric oxide in carcinogenesis. Mutat. Res. 305 2 (1994) 253-264
26. Pollet P., and Gellin S. Tetronic acids and derivatives. Part VI. A convenient synthesis of new 4-oxo-2-phenyl-2H-4,6-dihydrofuro-[3,4-d]thiazole and 4-oxo-4,6-dihydrofuro[3,4-c]furazan system. Synthesis 12 (1979) 977-979
27. Rubanyi G.M. Pathophysiology and Clinical Applications of Nitric Oxide Part A and B (1999), Hardwood Academic Publishers, Singapore
28. Sandhu J.K., and Birnboim H.C. Mutagenicity and cytotoxicity of reactive oxygen and nitrogen species in the MN-11 murine tumor cell line. Mutat Res. 379 2 (1997) 241-252
29. Singh N.P., McCoy M.T., Tice R.R., and Schneider E.L. A simple technique for quantitation of low levels of DNA damage in individual cells. Exp. Cell Res. 175 1 (1988) 184-191
30. Sorba G., Medana C., Di Stilo A., Cena C., Galli U., Fruttero R., and Gasco A. Water soluble furoxan derivatives as NO-prodrugs. J. Med. Chem. 40 4 (1997) 463-469
31. Wink D.A., Vodovotz Y., Laval J., Laval F., Dewhirst M.W., and Mitchell J.B. The multifaceted roles of nitric oxide in cancer. Carcinogenesis 19 5 (1998) 711-721
32. Zhuang J.C., and Wogan G.N. Growth and viability of macrophages continuously stimulated to produce nitric oxide. Proc. Natl. Acad. Sci. U.S.A. 94 22 (1997) 11875-11880